Peyronie’s disease: pharmacological treatments and limitations

Li, Eric V.; Esterquest, Robert; Pham, Minh; Panken, Evan J.; Amarasekera, Channa; Siebert, Aisha L.; Bajic, Petar; Levine, Laurence A.

doi:10.1080/17512433.2021.1903873

Cited by 10 publications

(3 citation statements)

References 91 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Various forms of oral, topical, and intralesional (collagenase clostridium histiolyticum) (Tsambarlis and Levine, 2018) treatments have been trialled in the acute phase along with extracorporeal shock wave therapy and penile traction (Vanni and Bennett, 2009). Intralesional injections have the best evidence for non-surgical treatment options for Peyronie’s disease (Li et al., 2021). However, research evidence does not support any successful outcomes with the use of oral or combination therapies.…”

Section: Managementmentioning

confidence: 99%

Peyronie’s disease and other common penile disorders

Shekhawat

2023

InnovAiT: Education and inspiration for general practice

View full text Add to dashboard Cite

Peyronie’s disease is a common condition affecting the penis and is characterised by fibrosis of the tunica albuginea of the penis. This condition was named after Francois Gigot de la Peyronie in 1749. This condition causes symptoms of curvature of the penis on erection, painful erection, or pain during intercourse, and can lead to emotional or psychological turmoil for the patient. People suffering from the disease can feel a lump or plaque in the shaft of the penis, which can lead to deformity or shortening of the penis. Balanitis, phimosis and paraphimosis, balanitis xerotica obliterans, penile cancer and congenital malformations are other common penile disorders presenting in general practice that require assessment, diagnosis, treatment and occasionally specialist referral.

show abstract

Section: Managementmentioning

confidence: 99%

Peyronie’s disease and other common penile disorders

Shekhawat

2023

InnovAiT: Education and inspiration for general practice

View full text Add to dashboard Cite

show abstract

“…These events lead to the phenotypic transition of potential precursors into myo broblasts, which in turn causes an imbalance in the production and breakdown of collagen. Finally, the continued buildup of extracellular matrix (ECM) results in the development of penile brosis and plaque [9] [10] . The fact that brosis often manifests in other regions in PD patients, such as Dupuytren's contracture in approximately 22% of PD patients [11] , suggests the possibility that PD may have a genetic predisposition [12] .…”

Section: Introductionmentioning

confidence: 99%

The 100 most-cited publications on Peyronie’s disease: A bibliometric analysis and visualization study

Chang

Gao

Shen³

et al. 2023

Preprint

View full text Add to dashboard Cite

Background: Over the past few decades, there has been a substantial increase in our understanding of Peyronie's disease (PD), improving our ability to diagnose and treat the disorder clinically. The goal of this study is to disclose the development trend of the PD field and provide resources for academics. It does this by providing the 100 most-cited publications in the field and conducting bibliometrics and visualization analysis on them. Methods: The SCI-E of WoSCC provided us with the top 100 most-cited publications in PD research, from which we took the following information: year of publication, annual citations, nation/region, institution, journal, author, and keywords. VOSviewer (version 1.6.18) was used for visual analysis to evaluate the keywords. Results: Through a standardized search, we ultimately found 1,019 papers in the field of PD research, from which we extracted the 100 works that had received the highest citations. The articles published between 1949 and 2016 have been cited between 73 and 338 times. The United States is a major contributor to PD research. The University of California, Los Angeles, is the institution with the largest number of articles. Levine LA, Lue TF, Gelbard MK and others are among the most authoritative authors in the field. Sixteen journals published the top 100 cited articles, with the Journal of Urology being the most influential in the field, with 47 publications. Erectile dysfunction (n=19) is the keyword with the highest frequency, indicating that PD-related erectile dysfunction is the leading focus of research in this field. Most of the keywords that have appeared in the past decade are related to the clinical treatment of PD. Therefore, we think the frontier of future research will be to maximize the improvement of male erectile function in the therapeutic therapy of PD. Conclusion: Our study uses bibliometrics and visualization analysis of the most important articles in the field of PD research to show the current state of research in this area, depict the history of research trends, and provide a forecast for the future growth of PD.

show abstract

“…Despite affecting 3–9% of men, current treatment is limited to surgery as non-surgical treatment has demonstrated limited efficacy [ 10 , 11 ]. Currently, the only non-surgical therapy remains the intralesional injection of collagenase [ 12 ], which has been withdrawn from the market recently [ 13 ]. Both surgery and collagenase are used as a last resort at late stages of the disease.…”

Section: Introductionmentioning

confidence: 99%

Phenotypic screening of 1,953 FDA-approved drugs reveals 26 hits with potential for repurposing for Peyronie’s disease

et al. 2022

View full text Add to dashboard Cite

Drug repurposing has been shown to bring safe medications to new patient populations, as recently evidenced by the COVID-19 pandemic. We investigated whether we could use phenotypic screening to repurpose drugs for the treatment of Peyronie’s disease (PD). PD is a fibrotic disease characterised by continued myofibroblast presence and activity leading to formation of a plaque in the penile tunica albuginea (TA) that can cause pain during erection, erectile dysfunction, and penile deformity. PD affects 3–9% of men with treatment options limited to surgery or injection of collagenase which can only be utilised at late stages after the plaque is formed. Currently there are no approved medications that can be offered to patients presenting with early disease before the formation of the plaque. Drug repurposing may therefore be the ideal strategy to identify medical treatments to address this unmet medical need in early PD. We used primary human fibroblasts from PD patients in a phenotypic screening assay that measures TGF-β1-induced myofibroblast transformation which is the main cellular phenotype that drives the pathology in early PD. A library of FDA-approved 1,953 drugs was screened in duplicate wells at a single concentration (10 μM) in presence of TGF-β1. The myofibroblast marker α-SMA was quantified after 72h incubation. A positive control of SB-505124 (TGF-β1 receptor antagonist) was included on each plate. Hits were defined as showing >80% inhibition, whilst retaining >80% cell viability. 26 hits (1.3%) were identified which were divided into the following main groups: anti-cancer drugs, anti-inflammation, neurology, endocrinology, and imaging agents. Five of the top-ten drugs that increase myofibroblast-transformation appear to act on VEGFR. This is the first phenotypic screening of FDA-approved drugs for PD and our results suggest that it is a viable method to predict drugs with potential for repurposing to treat early PD.

show abstract

Peyronie’s disease: pharmacological treatments and limitations

Cited by 10 publications

References 91 publications

Peyronie’s disease and other common penile disorders

Peyronie’s disease and other common penile disorders

The 100 most-cited publications on Peyronie’s disease: A bibliometric analysis and visualization study

Phenotypic screening of 1,953 FDA-approved drugs reveals 26 hits with potential for repurposing for Peyronie’s disease

Contact Info

Product

Resources

About